Background: Neurodegenerative disorders (NDs) are typically referred to Alzheimer's
disease, Parkinson's diseases, amyotrophic lateral sclerosis and prion disease. These are …

The preeminent treatments for neurodegenerative disease are often unavailable due to the
poor accessibility of therapeutic drugs. Moreover, the blood–brain barrier (BBB) effectively …

Alzheimer's disease (AD) is a progressive deterioration of brain function, initially
characterized by cognitive deficits, with loss of recent memory and language ability …

Neurons and their connecting axons gradually degenerate in neurodegenerative diseases
(NDs), leading to dysfunctionality of the neuronal cells and eventually their death. Drug …

Neurodegenerative diseases (NDs) represent a heterogeneous group of aging-related
disorders featured by progressive impairment of motor and/or cognitive functions, often …

The blood–brain barrier is the interface between the blood and brain, impeding the passage
of most circulating cells and molecules, protecting the latter from foreign substances, and …

Drug delivery to central nervous system (CNS) diseases is one of the most challenging
tasks. The innate blood-brain barrier (BBB) and the blood-cerebrospinal fluid (BCSF) barrier …

New nanotechnology strategies for enhancing drug delivery in brain disorders have recently
received increasing attention from drug designers. The treatment of neurological conditions …

Human health is severely hampered by a majority of the neurological disorders such as the
brain tumors, degenerative Alzheimer's disease, Parkinson's disease and those involving …

With an aging population that has been increasing in recent years, the need for the
development of therapeutic approaches for treatment of neurodegenerative disorders (ND) …